Journal article
Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma
K Jones, F Vari, C Keane, P Crooks, JP Nourse, LA Seymour, D Gottlieb, D Ritchie, D Gill, MK Gandhi
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2013
Abstract
Purpose: Candidate circulating disease response biomarkers for classical Hodgkin lymphoma (cHL) might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. HRS cells are sparse within the diseased node, whereas benign CD163+ M2 tissue-associated macrophages (TAM) are prominent. CD163+ cells within the malignant node may be prognostic, but there is no data on serum CD163 (sCD163). The HRS-specific serum protein sTARC shows promise as a disease response biomarker. Tumor-specific and tumor-infiltrating circulating biomarkers have not been compared previously. Experimental Design: We prospectively measured sCD163 and sTARC in 221 samples from 47 patients with Ho..
View full abstractGrants
Funding Acknowledgements
D. Gottlieb has a commercial research grant from Celgene and honoraria from speakers' bureau from Gilead. No potential conflicts of interest were disclosed by the other authors.This was an Australasian Leukaemia & Lymphoma Group sponsored study. The authors thank Susan Arnold for her assistance with data collection and Clay Winterford for immunohistochemistry staining.Work in the Clinical Immunohaematology laboratory is sponsored by the National Health and Medical Research Council (Australia), Leukaemia Foundation (Australia), Cancer Council of Queensland, and Queensland Office of Health and Medical Research. K. L. Jones is supported by the Leukaemia Foundation (Australia), the Australian Centre for Vaccine Development, and QIMR.